Safety of AS03-adjuvanted influenza vaccines: A review of the evidence

•Non-clinical studies raised no safety concerns regarding the use of AS03.•In clinical trials, AS03-adjuvanted influenza vaccines were generally well tolerated.•Post-licensure data showed a favourable benefit-risk profile in various populations.•The increased risk of narcolepsy with Pandemrix may no...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2019-05, Vol.37 (23), p.3006-3021
Hauptverfasser:	Cohet, Catherine, van der Most, Robbert, Bauchau, Vincent, Bekkat-Berkani, Rafik, Doherty, T. Mark, Schuind, Anne, Tavares Da Silva, Fernanda, Rappuoli, Rino, Garçon, Nathalie, Innis, Bruce L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvant system Adjuvants Age Amino acid sequence Antigens Avian flu Birth weight CD4 antigen Clinical trials Congenital diseases Hemagglutinins Immunological tolerance Influenza Licenses Lymphocytes Lymphocytes T Medical research Mimicry Miscarriage Narcolepsy Pain Pandemics Pharmacology Pharmacovigilance Population Population studies Pregnancy Premature birth Reactogenicity Safety Sleep disorders Stillbirth Swine flu Toxicology Vaccine Vaccines Virions Womens health
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!